Anderson K M, Rubenstein M, Alrefai W A, Dudeja P, Tsui P, Harris J E
Hektoen Institute, Department of Biochemistry, Rush University Medical Center, University of Illinois and West Side V.A. Chicago, IL 60612, USA.
Anticancer Res. 2004 Sep-Oct;24(5A):2601-15.
MK 886, a 5-lipoxygenase inhibitor, induces a type 1 "apoptotic" form of programmed cell death in Bcl-2-positive U937 monoblastoid cells. In Ca2+-depleted, nonpermeabilized U937 cells studied with MK 886 in a Ca2+-free medium, an acute increase in Ca2+ occured within 10 to 20 seconds, detected with fura-2 measured with a spectrofluorimeter.
The increased fluorescence was nuclear in location, as judged by confocal microscopy. The antioxidant, N-acetyl-L-cysteine, three agents that inhibit mitochondrialfunction at identified sites, antimycin A, atractyloside and cyclosporin A, the L/N-channel inhibitor, loperamide and BAPTA, an intracellular Ca+ chelator preloaded into cells each reduced the extent or prevented the acute MK 886-induced rise in Ca2+, as determined by radiometric detection. Rhodamine-2, a more selective mitochondrial Ca2+ probe, provided no evidence for nuclear Ca2+ originating from that extra-nuclear site or from the endoplasmic reticulum. With 2', 7'-dichloro-dihydrofluorescein-labelled cells to detect reactive oxygen species, MK 886 increased the initial fluorescent signal from a number of intracellular, largely extra-nuclear sites, including mitochondria. Two chemicals that inhibit the function of Bcl-2, HA14-1 and 2-methyl-antimycin A3, reduced the Ca2+ response to MK 886, if pre-incubated with the Bcl-2-positive U937 cells at 37 degrees C for several hours. MK 886 was previously shown to induce reactive oxygen species and a fall in mitochondrial membrane potential in both Bcl-2-positive U937 and in Bcl-2-negative PC-3 prostate and panc-1 pancreatic cancer cells. The latter solid tumor cells undergo an atypical "type 2" PCD without an acute rise in nuclear Ca2+.
These results are consistent with an MK 886-induced increase of reactive oxygen species from intra-cellular sites including mitochondria which release Ca2+ located primarily at or near nuclei. These events may involve Bcl-2 participating in some form of Ca2+ channel and nuclear Ca2+ binding proteins undergoing conformational changes due to reactive oxygen species. Reasons for the different PCD responses in Bcl-2 positive lympho-hematopoietic compared to Bcl-2-negative solid cancer cell lines, respectively with and without the induced nuclear Ca2+ signal, remain to be defined.
MK 886是一种5-脂氧合酶抑制剂,可在Bcl-2阳性的U937单核细胞样细胞中诱导1型“凋亡”形式的程序性细胞死亡。在用MK 886于无钙培养基中研究的钙耗尽、未通透的U937细胞中,在10至20秒内出现了钙的急性增加,这是用荧光分光光度计测量的fura-2检测到的。
通过共聚焦显微镜判断,增加的荧光位于细胞核内。抗氧化剂N-乙酰-L-半胱氨酸、三种在特定位点抑制线粒体功能的试剂(抗霉素A、苍术苷和环孢素A)、L/N通道抑制剂洛哌丁胺以及预先加载到细胞中的细胞内钙螯合剂BAPTA,每种都降低了或阻止了MK 886诱导的钙急性升高,这是通过放射检测确定的。罗丹明-2是一种更具选择性的线粒体钙探针,没有提供证据表明核钙来自核外位点或内质网。用2',7'-二氯二氢荧光素标记的细胞检测活性氧,MK 886增加了来自许多细胞内、主要是核外位点(包括线粒体)的初始荧光信号。两种抑制Bcl-2功能的化学物质HA14-1和2-甲基抗霉素A3,如果在37℃下与Bcl-2阳性的U937细胞预孵育数小时,会降低对MK 886的钙反应。先前已表明,MK 886在Bcl-2阳性的U937细胞以及Bcl-2阴性的PC-3前列腺癌细胞和panc-1胰腺癌细胞中均可诱导活性氧产生并导致线粒体膜电位下降。后一种实体瘤细胞经历非典型的“2型”程序性细胞死亡,而核钙没有急性升高。
这些结果与MK 886诱导细胞内位点(包括线粒体)产生活性氧增加一致,这些位点释放主要位于细胞核或其附近的钙。这些事件可能涉及Bcl-2以某种形式参与钙通道,以及核钙结合蛋白因活性氧而发生构象变化。Bcl-2阳性的淋巴造血细胞系与Bcl-2阴性的实体癌细胞系中程序性细胞死亡反应不同的原因,分别是有或没有诱导的核钙信号,仍有待确定。